Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2004 1
2005 2
2006 5
2007 4
2008 2
2009 4
2010 4
2011 7
2012 5
2013 8
2014 6
2015 10
2016 5
2017 5
2018 7
2019 10
2020 5
2021 7
2022 7
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Actively personalized vaccination trial for newly diagnosed glioblastoma.
Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. Hilf N, et al. Among authors: gouttefangeas c. Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Nature. 2019. PMID: 30568303 Clinical Trial.
Personalized cancer vaccines: adjuvants are important, too.
Gouttefangeas C, Rammensee HG. Gouttefangeas C, et al. Cancer Immunol Immunother. 2018 Dec;67(12):1911-1918. doi: 10.1007/s00262-018-2158-4. Epub 2018 Apr 11. Cancer Immunol Immunother. 2018. PMID: 29644387 Free PMC article. Review.
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma.
Löffler MW, Gori S, Izzo F, Mayer-Mokler A, Ascierto PA, Königsrainer A, Ma YT, Sangro B, Francque S, Vonghia L, Inno A, Avallone A, Ludwig J, Alcoba DD, Flohr C, Aslan K, Mendrzyk R, Schuster H, Borrelli M, Valmori D, Chaumette T, Heidenreich R, Gouttefangeas C, Forlani G, Tagliamonte M, Fusco C, Penta R, Iñarrairaegui M, Gnad-Vogt U, Reinhardt C, Weinschenk T, Accolla RS, Singh-Jasuja H, Rammensee HG, Buonaguro L. Löffler MW, et al. Among authors: gouttefangeas c. Clin Cancer Res. 2022 Jun 13;28(12):2555-2566. doi: 10.1158/1078-0432.CCR-21-4424. Clin Cancer Res. 2022. PMID: 35421231 Clinical Trial.
Immunorejuvenation in the elderly.
Pawelec G, Koch S, Gouttefangeas C, Wikby A. Pawelec G, et al. Among authors: gouttefangeas c. Rejuvenation Res. 2006 Spring;9(1):111-6. doi: 10.1089/rej.2006.9.111. Rejuvenation Res. 2006. PMID: 16608407 Review.
A framework for T cell assays.
Britten CM, van der Burg SH, Gouttefangeas C. Britten CM, et al. Among authors: gouttefangeas c. Oncotarget. 2015 Nov 3;6(34):35143-4. doi: 10.18632/oncotarget.6181. Oncotarget. 2015. PMID: 26506424 Free PMC article. No abstract available.
CAF-immune cell crosstalk and its impact in immunotherapy.
Maia A, Schöllhorn A, Schuhmacher J, Gouttefangeas C. Maia A, et al. Among authors: gouttefangeas c. Semin Immunopathol. 2023 Mar;45(2):203-214. doi: 10.1007/s00281-022-00977-x. Epub 2022 Dec 8. Semin Immunopathol. 2023. PMID: 36480035 Free PMC article. Review.
Defining the critical hurdles in cancer immunotherapy.
Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Dis… See abstract for full author list ➔ Fox BA, et al. Among authors: gouttefangeas c. J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214. J Transl Med. 2011. PMID: 22168571 Free PMC article.
Radiofrequency ablation: the percutaneous approach.
Pereira P, Boss A, Clasen S, Gouttefangeas C, Schmidt D, Claussen CD. Pereira P, et al. Among authors: gouttefangeas c. Recent Results Cancer Res. 2006;167:39-52. doi: 10.1007/3-540-28137-1_3. Recent Results Cancer Res. 2006. PMID: 17044295 Review. No abstract available.
Immunotherapy of renal cell carcinoma.
Gouttefangeas C, Stenzl A, Stevanović S, Rammensee HG. Gouttefangeas C, et al. Cancer Immunol Immunother. 2007 Jan;56(1):117-28. doi: 10.1007/s00262-006-0172-4. Epub 2006 May 5. Cancer Immunol Immunother. 2007. PMID: 16676181 Free PMC article. Review.
87 results